{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:36:41Z","timestamp":1794573401889,"version":"4.9.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The main purpose was to evaluate the efficacy and tolerability of different medications used to treat bulimia nervosa (BN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Randomized controlled trials (RCTs) were identified from published sources through searches in PubMed, Cochrane Library, Web of Science, and Embase from inception to November 2022. Primary outcomes were changes in the frequency of binge eating episodes and vomiting episodes from baseline to endpoint. Secondary outcomes were differences in the improvement of scores in depressive symptoms, tolerability (dropout due to adverse events) and weight change.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The literature search ultimately included 11 drugs, 33 studies and 6 types of drugs, 8 trials with TCAs (imipramine, desipramine), 14 with SSRIs (fluoxetine, citalopram and fluvoxamine), 6 with MAOIs (phenelzine, moclobemide and brofaromine), 3 with antiepileptic drugs (topiramate), 1 with mood stabilizers (lithium), and 1 with amphetamine-type appetite suppressant (fenfluramine). The reduction in binge eating episodes was more likely due to these drugs than the placebo, and the SMD was -0.4 (95% CI -0.61\u2009~\u2009-0.19); the changes in the frequency of vomiting episodes (SMD\u2009=\u2009-0.16, 95% CI -0.3\u2009~\u2009-0.03); weight (WMD\u2009=\u2009-3.05, 95% CI -5.97\u2009~\u2009-0.13); and depressive symptoms (SMD\u2009=\u2009-0.32, 95% CI -0.51\u2009~\u2009-0.13). However, no significant difference was found in dropout due to adverse events (RR\u2009=\u20091.66, 95% CI 1.14\u2009~\u20092.41).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This meta-analysis indicates that most pharmacotherapies decreased the frequency of binge-eating and vomiting episodes, body weight, and depressive symptoms in BN patients, but the efficacy was not significant. In each drug the efficacy is different, treating different aspects, different symptoms to improve the clinical performance of bulimia nervosa.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40360-023-00713-7","type":"journal-article","created":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T18:01:36Z","timestamp":1701540096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Sijie","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongkai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,2]]},"reference":[{"issue":"3","key":"713_CR1","first-page":"36","volume":"28","author":"M Guha","year":"1997","unstructured":"Guha M. Diagnostic and Statistical Manual of mental disorders: DSM-5 (5th edition). Ref Rev. 1997;28(3):36\u20137.","journal-title":"Ref Rev"},{"issue":"4","key":"713_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cppeds.2017.02.004","volume":"47","author":"M Castillo","year":"2017","unstructured":"Castillo M, Weiselberg E. Bulimia Nervosa\/Purging disorder. Curr Probl Pediatr Adolesc Health Care. 2017;47(4):85\u201394.","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"issue":"6","key":"713_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/YCO.0000000000000739","volume":"34","author":"AE van Eeden","year":"2021","unstructured":"van Eeden AE, van Hoeken D, Hoek HW. Incidence, prevalence and mortality of anorexia nervosa and bulimia nervosa. Curr Opin Psychiatry. 2021;34(6):515\u201324.","journal-title":"Curr Opin Psychiatry"},{"issue":"6","key":"713_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/YCO.0000000000000278","volume":"29","author":"A Keski-Rahkonen","year":"2016","unstructured":"Keski-Rahkonen A, Mustelin L. Epidemiology of eating disorders in Europe: prevalence, incidence, comorbidity, course, consequences, and risk factors. Curr Opin Psychiatry. 2016;29(6):340\u20135.","journal-title":"Curr Opin Psychiatry"},{"key":"713_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jad.2015.06.039","volume":"185","author":"N Godart","year":"2015","unstructured":"Godart N, et al. Mood disorders in eating disorder patients: prevalence and chronology of ONSET. J Affect Disord. 2015;185:115\u201322.","journal-title":"J Affect Disord"},{"issue":"1","key":"713_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0149-7634(94)00044-2","volume":"19","author":"C Advokat","year":"1995","unstructured":"Advokat C, Kutlesic V. Pharmacotherapy of the eating disorders: a commentary. Neurosci Biobehav Rev. 1995;19(1):59\u201366.","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"713_CR7","first-page":"46","volume":"91","author":"BC Harrington","year":"2015","unstructured":"Harrington BC, et al. Initial evaluation, diagnosis, and treatment of anorexia nervosa and bulimia nervosa. Am Fam Phys. 2015;91(1):46\u201352.","journal-title":"Am Fam Phys"},{"issue":"16","key":"713_CR8","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1017\/S0033291718001071","volume":"48","author":"E Slade","year":"2018","unstructured":"Slade E, et al. Treatments for bulimia nervosa: a network meta-analysis. Psychol Med. 2018;48(16):2629\u201336.","journal-title":"Psychol Med"},{"issue":"6","key":"713_CR9","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1017\/S0033291718003525","volume":"49","author":"J Svaldi","year":"2019","unstructured":"Svaldi J, et al. Efficacy of psychotherapies and pharmacotherapies for Bulimia nervosa. Psychol Med. 2019;49(6):898\u2013910.","journal-title":"Psychol Med"},{"issue":"6","key":"713_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/archpsyc.1993.01820180009001","volume":"50","author":"CG Fairburn","year":"1993","unstructured":"Fairburn CG, et al. Psychotherapy and bulimia nervosa. Longer-term effects of interpersonal psychotherapy, behavior therapy, and cognitive behavior therapy. Arch Gen Psychiatry. 1993;50(6):419.","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"713_CR11","doi-asserted-by":"publisher","first-page":"459-","DOI":"10.1001\/archpsyc.57.5.459","volume":"57","author":"WS Agras","year":"2000","unstructured":"Agras WS, et al. A multicenter comparison of cognitive-behavioral therapy and interpersonal psychotherapy for bulimia nervosa. Arch Gen Psychiatry. 2000;57(5):459-.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"713_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0883-9417(95)80033-6","volume":"9","author":"BE Wolfe","year":"1995","unstructured":"Wolfe BE. Dimensions of response to antidepressant agents in bulimia nervosa: a review. Arch Psychiatr Nurs. 1995;9(3):111\u201321.","journal-title":"Arch Psychiatr Nurs"},{"issue":"5","key":"713_CR13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.genhosppsych.2008.02.002","volume":"30","author":"B Arbaizar","year":"2008","unstructured":"Arbaizar B, G\u00f3mez-Acebo I, Llorca J. Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review. Gen Hosp Psychiatry. 2008;30(5):471\u20135.","journal-title":"Gen Hosp Psychiatry"},{"key":"713_CR14","doi-asserted-by":"crossref","unstructured":"McInnes FMD, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford T, Cohen JF, Deeks JJ, Gatsonis C, Hooft L, Hunt HA, Hyde CJ, Korevaar DA, Leeflang MMG, Macaskill P, Reitsma JB, Rodin R, Rutjes AWS, Salameh JP, Stevens A, Takwoingi Y, Tonelli M, Weeks L, Whiting P, Willis BH. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: The PRISMA-DTA statement. JAMA. 2018:319;388\u201396.","DOI":"10.1001\/jama.2017.19163"},{"issue":"2","key":"713_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1177\/070674378803300211","volume":"33","author":"J Barlow","year":"1988","unstructured":"Barlow J, et al. Treatment of bulimia with desipramine: a double-blind crossover study. Can J Psychiatry Revue Canadienne De Psychiatrie. 1988;33(2):129\u201333.","journal-title":"Can J Psychiatry Revue Canadienne De Psychiatrie"},{"issue":"1","key":"713_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/070674378903400107","volume":"34","author":"JH Blouin","year":"1989","unstructured":"Blouin JH, et al. Bulimia: independence of antibulimic and antidepressant properties of desipramine. Can J Psychiatry. 1989;34(1):24\u20139.","journal-title":"Can J Psychiatry"},{"issue":"3","key":"713_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1089\/104454603322572660","volume":"13","author":"LA Kotler","year":"2003","unstructured":"Kotler LA, et al. An open trial of fluoxetine for adolescents with bulimia nervosa. J Child Adolesc Psychopharmacol. 2003;13(3):329\u201335.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"713_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/eat.20018","volume":"36","author":"DM Sloan","year":"2004","unstructured":"Sloan DM, et al. Efficacy of sertraline for bulimia nervosa. Int J Eat Disord. 2004;36(1):48\u201354.","journal-title":"Int J Eat Disord"},{"issue":"1","key":"713_CR19","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/S0006-3223(97)88008-0","volume":"42","author":"L Fern\u00e1ndez-Suarez","year":"1997","unstructured":"Fern\u00e1ndez-Suarez L, et al. Open trial of fluvoxamine in the treatment of patients with bullmia nervosa. Biol Psychiatry. 1997;42(1):S-570.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"713_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/eat.20078","volume":"37","author":"R Sysko","year":"2005","unstructured":"Sysko R, Walsh BT, Fairburn CG. Eating disorder examination-questionnaire as a measure of change in patients with bulimia nervosa. Int J Eat Disord. 2005;37(2):100\u20136.","journal-title":"Int J Eat Disord"},{"issue":"3","key":"713_CR21","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1177\/026988110401800314","volume":"18","author":"S Fassino","year":"2004","unstructured":"Fassino S, et al. Use of reboxetine in bulimia nervosa: a pilot study. J Psychopharmacol. 2004;18(3):423\u20138.","journal-title":"J Psychopharmacol"},{"key":"713_CR22","doi-asserted-by":"crossref","unstructured":"Vega M, et al. Fluoxetine treatment of bulimia nervosa. Eur Neuropsychopharmacol. 1995;5(3):287\u20138.","DOI":"10.1016\/0924-977X(95)90404-2"},{"issue":"4","key":"713_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/00004714-198808000-00005","volume":"8","author":"AG Blouin","year":"1988","unstructured":"Blouin AG, et al. Treatment of bulimia with fenfluramine and desipramine. J Clin Psychopharmacol. 1988;8(4):261\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"713_CR24","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1176\/ajp.150.5.770","volume":"150","author":"DS Goldbloom","year":"1993","unstructured":"Goldbloom DS, Olmsted MP. Pharmacotherapy of bulimia nervosa with fluoxetine: assessment of clinically significant attitudinal change. Am J Psychiatry. 1993;150(5):770\u20134.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"713_CR25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/archpsyc.1990.01810140049008","volume":"47","author":"JE Mitchell","year":"1990","unstructured":"Mitchell JE, et al. A comparison study of antidepressants and structured intensive group psychotherapy in the treatment of bulimia nervosa. Arch Gen Psychiatry. 1990;47(2):149\u201357.","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 1","key":"713_CR26","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1097\/00002826-198901001-00007","volume":"12","author":"JI Hudson","year":"1989","unstructured":"Hudson JI, et al. Treatment of bulimia nervosa with trazodone: short-term response and long-term follow-up. Clin Neuropharmacol. 1989;12(Suppl 1):S38-46.","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"713_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/00004714-198908000-00004","volume":"9","author":"HG Pope Jr","year":"1989","unstructured":"Pope HG Jr, et al. A placebo-controlled study of trazodone in bulimia nervosa. J Clin Psychopharmacol. 1989;9(4):254\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"713_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1055\/s-2007-979488","volume":"30","author":"MM Fichter","year":"1997","unstructured":"Fichter MM, et al. Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa. Pharmacopsychiatry. 1997;30(3):85\u201392.","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"713_CR29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/BF02849936","volume":"22","author":"W Milano","year":"2005","unstructured":"Milano W, et al. Treatment of bulimia nervosa with fluvoxamine: a randomized controlled trial. Adv Ther. 2005;22(3):278\u201383.","journal-title":"Adv Ther"},{"issue":"5","key":"713_CR30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/01.jcp.0000138776.32891.3e","volume":"24","author":"U Schmidt","year":"2004","unstructured":"Schmidt U, et al. Fluvoxamine and graded psychotherapy in the treatment of bulimia nervosa: a randomized, double-blind, placebo-controlled, multicenter study of short-term and long-term pharmacotherapy combined with a stepped care approach to psychotherapy. J Clin Psychopharmacol. 2004;24(5):549\u201352.","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"713_CR31","first-page":"262","volume":"49","author":"RL Horne","year":"1988","unstructured":"Horne RL, et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry. 1988;49(7):262\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"713_CR32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/archpsyc.1986.01800020092012","volume":"43","author":"PL Hughes","year":"1986","unstructured":"Hughes PL, et al. Treating bulimia with desipramine. A double-blind, placebo-controlled study. Arch Gen Psychiatry. 1986;43(2):182\u20136.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"713_CR33","first-page":"391","volume":"8","author":"SH Kennedy","year":"1989","unstructured":"Kennedy SH, et al. A Trial of Isocarboxazid in the treatment of Bulimia Nervosa. J Clin Psychopharmacol. 1989;8(6):391\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"713_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/(SICI)1098-108X(199901)25:1<19::AID-EAT3>3.0.CO;2-3","volume":"25","author":"DJ Goldstein","year":"1999","unstructured":"Goldstein DJ, et al. Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. Int J Eat Disord. 1999;25(1):19\u201327.","journal-title":"Int J Eat Disord"},{"issue":"4","key":"713_CR35","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/BF02850155","volume":"21","author":"W Milano","year":"2004","unstructured":"Milano W, et al. Treatment of bulimia nervosa with sertraline: a randomized controlled trial. Adv Ther. 2004;21(4):232\u20137.","journal-title":"Adv Ther"},{"issue":"1","key":"713_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0005-7967(94)90082-5","volume":"32","author":"H Leitenberg","year":"1994","unstructured":"Leitenberg H, et al. Comparison of cognitive-behavior therapy and desipramine in the treatment of bulimia nervosa. Behav Res Ther. 1994;32(1):37\u201345.","journal-title":"Behav Res Ther"},{"issue":"Suppl 2","key":"713_CR37","first-page":"195","volume":"15","author":"EJ Sabine","year":"1983","unstructured":"Sabine EJ, et al. Bulimia nervosa: a placebo controlled double-blind therapeutic trial of mianserin. Br J Clin Pharmacol. 1983;15(Suppl 2):195\u2013202.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"713_CR38","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00004850-199300840-00014","volume":"8","author":"A Wood","year":"1993","unstructured":"Wood A. Pharmacotherapy of bulimia nervosa\u2013experience with fluoxetine. Int Clin Psychopharmacol. 1993;8(4):295\u20139.","journal-title":"Int Clin Psychopharmacol"},{"key":"713_CR39","doi-asserted-by":"crossref","unstructured":"Group, F.B.N.C.S. Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Fluoxetine Bulimia Nervosa Collaborative Study Group. Archives of General Psychiatry. 1992:49(2);139\u201347.","DOI":"10.1001\/archpsyc.1992.01820020059008"},{"key":"713_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.cct.2017.10.007","volume":"64","author":"SS Dalai","year":"2017","unstructured":"Dalai SS, et al. Study protocol and rationale for a randomized double-blinded crossover trial of phentermine-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa. Contemp Clin Trials. 2017;64:173\u20138.","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"713_CR41","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/eat.23192","volume":"53","author":"DL Safer","year":"2020","unstructured":"Safer DL, et al. A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa. Int J Eat Disord. 2020;53(2):266\u201377.","journal-title":"Int J Eat Disord"},{"issue":"4","key":"713_CR42","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/00004714-198408000-00003","volume":"4","author":"JE Mitchell","year":"1984","unstructured":"Mitchell JE, Groat R. A placebo-controlled, double-blind trial of amitriptyline in bulimia. J Clin Psychopharmacol. 1984;4(4):186\u201393.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"713_CR43","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1176\/ajp.155.4.548","volume":"155","author":"E Attia","year":"1998","unstructured":"Attia E, et al. Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry. 1998;155(4):548\u201351.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"713_CR44","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1192\/bjp.166.5.660","volume":"166","author":"DJ Goldstein","year":"1995","unstructured":"Goldstein DJ, et al. Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa research group. Br J Psychiatry. 1995;166(5):660\u20136.","journal-title":"Br J Psychiatry"},{"issue":"9","key":"713_CR45","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0005-7967(97)00041-7","volume":"35","author":"DS Goldbloom","year":"1997","unstructured":"Goldbloom DS, et al. A randomized controlled trial of fluoxetine and cognitive behavioral therapy for bulimia nervosa: short-term outcome. Behav Res Ther. 1997;35(9):803\u201311.","journal-title":"Behav Res Ther"},{"issue":"3","key":"713_CR46","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.biopsych.2004.11.002","volume":"57","author":"CM Grilo","year":"2005","unstructured":"Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biol Psychiatry. 2005;57(3):301\u20139.","journal-title":"Biol Psychiatry"},{"issue":"8","key":"713_CR47","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1176\/appi.ajp.157.8.1332","volume":"157","author":"BT Walsh","year":"2000","unstructured":"Walsh BT, et al. Fluoxetine for bulimia nervosa following poor response to psychotherapy. Am J Psychiatry. 2000;157(8):1332\u20134.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"713_CR48","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1176\/appi.ajp.159.1.96","volume":"159","author":"SJ Romano","year":"2002","unstructured":"Romano SJ, et al. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry. 2002;159(1):96\u2013102.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"713_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-2007-1014424","volume":"24","author":"MM Fichter","year":"1991","unstructured":"Fichter MM, et al. Fluoxetine versus placebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy. Pharmacopsychiatry. 1991;24(1):1\u20137.","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"713_CR50","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3109\/00048679709065073","volume":"31","author":"PJ Beumont","year":"1997","unstructured":"Beumont PJ, et al. Intensive nutritional counselling in bulimia nervosa: a role for supplementation with fluoxetine? Aust N Z J Psychiatry. 1997;31(4):514\u201324.","journal-title":"Aust N Z J Psychiatry"},{"issue":"3","key":"713_CR51","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/erv.452","volume":"10","author":"C Jacobi","year":"2002","unstructured":"Jacobi C, Dahme B, Dittmann R. Cognitive-behavioural, fluoxetine and combined treatment for bulimia nervosa: short- and long-term results. Eur Eat Disord Rev. 2002;10(3):179\u201398.","journal-title":"Eur Eat Disord Rev"},{"issue":"4","key":"713_CR52","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3109\/08039489509011912","volume":"49","author":"R Kanerva","year":"1994","unstructured":"Kanerva R, Rissanen A, Sarna S. Fluoxetine in the treatment of anxiety, depressive symptoms, and eating-related symptoms in bulimia nervosa. Nord Psyk Medl. 1994;49(4):237\u201342.","journal-title":"Nord Psyk Medl"},{"issue":"7","key":"713_CR53","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1176\/ajp.147.7.876","volume":"147","author":"MD Marcus","year":"1990","unstructured":"Marcus MD, et al. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry. 1990;147(7):876\u201381.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"713_CR54","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/01.jcp.0000150222.31007.a9","volume":"25","author":"C Sundblad","year":"2005","unstructured":"Sundblad C, et al. Effects of the androgen antagonist flutamide and the serotonin reuptake inhibitor citalopram in bulimia nervosa: a placebo-controlled pilot study. J Clin Psychopharmacol. 2005;25(1):85\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"713_CR55","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/eat.20202","volume":"38","author":"C Nickel","year":"2005","unstructured":"Nickel C, et al. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int J Eat Disord. 2005;38(4):295\u2013300.","journal-title":"Int J Eat Disord"},{"issue":"11","key":"713_CR56","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.4088\/JCP.v64n1109","volume":"64","author":"SP Hoopes","year":"2003","unstructured":"Hoopes SP, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry. 2003;64(11):1335\u201341.","journal-title":"J Clin Psychiatry"},{"key":"713_CR57","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1192\/bjp.162.5.597","volume":"162","author":"TA Fahy","year":"1993","unstructured":"Fahy TA, Eisler I, Russell GF. A placebo-controlled trial of d-fenfluramine in bulimia nervosa. Br J Psychiatry. 1993;162:597\u2013603.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"713_CR58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00004850-200101000-00003","volume":"16","author":"MO Carruba","year":"2001","unstructured":"Carruba MO, et al. Efficacy and tolerability of moclobemide in bulimia nervosa: a placebo-controlled trial. Int Clin Psychopharmacol. 2001;16(1):27\u201332.","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"713_CR59","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1176\/ajp.140.5.554","volume":"140","author":"HG Pope Jr","year":"1983","unstructured":"Pope HG Jr, et al. Bulimia treated with imipramine: a placebo-controlled, double-blind study. Am J Psychiatry. 1983;140(5):554\u20138.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"713_CR60","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/ajcn\/53.4.865","volume":"53","author":"SA Alger","year":"1991","unstructured":"Alger SA, et al. Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects. Am J Clin Nutr. 1991;53(4):865\u201371.","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"713_CR61","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/1098-108X(198701)6:1<29::AID-EAT2260060105>3.0.CO;2-2","volume":"6","author":"MD Agras","year":"1987","unstructured":"Agras MD, et al. Imipramine in the treatment of bulimia: a double-blind controlled study. Int J Eat Disord. 1987;6(1):29\u201338.","journal-title":"Int J Eat Disord"},{"issue":"1","key":"713_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/1098-108X(199401)15:1<1::AID-EAT2260150102>3.0.CO;2-E","volume":"15","author":"R Rothschild","year":"1994","unstructured":"Rothschild R, et al. A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives. Int J Eat Disord. 1994;15(1):1\u20139.","journal-title":"Int J Eat Disord"},{"issue":"11","key":"713_CR63","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1176\/ajp.147.11.1509","volume":"147","author":"UD McCann","year":"1990","unstructured":"McCann UD, Agras WS. Successful treatment of nonpurging bulimia nervosa with desipramine: a double-blind, placebo-controlled study. Am J Psychiatry. 1990;147(11):1509\u201313.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"713_CR64","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1176\/ajp.149.1.82","volume":"149","author":"WS Agras","year":"1992","unstructured":"Agras WS, et al. Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison. Am J Psychiatry. 1992;149(1):82\u20137.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"713_CR65","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1176\/ajp.154.4.523","volume":"154","author":"BT Walsh","year":"1997","unstructured":"Walsh BT, et al. Medication and psychotherapy in the treatment of bulimia nervosa. Am J Psychiatry. 1997;154(4):523\u201331.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"713_CR66","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1176\/ajp.148.9.1206","volume":"148","author":"BT Walsh","year":"1991","unstructured":"Walsh BT, et al. Long-term outcome of antidepressant treatment for bulimia nervosa. Am J Psychiatry. 1991;148(9):1206\u201312.","journal-title":"Am J Psychiatry"},{"issue":"11","key":"713_CR67","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/archpsyc.1983.01790220095015","volume":"41","author":"BT Walsh","year":"1984","unstructured":"Walsh BT, et al. Treatment of bulimia with phenelzine. A double-blind, placebo-controlled study. Arch Gen Psychiatry. 1984;41(11):1105\u20139.","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"713_CR68","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/archpsyc.1988.01800290091011","volume":"45","author":"BT Walsh","year":"1988","unstructured":"Walsh BT, et al. Phenelzine vs placebo in 50 patients with bulimia. Arch Gen Psychiatry. 1988;45(5):471\u20135.","journal-title":"Arch Gen Psychiatry"},{"issue":"2\u20133","key":"713_CR69","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/0022-3956(85)90058-5","volume":"19","author":"BT Walsh","year":"1985","unstructured":"Walsh BT, et al. A double-blind trial of phenelzine in bulimia. J Psychiatr Res. 1985;19(2\u20133):485\u20139.","journal-title":"J Psychiatr Res"},{"issue":"6","key":"713_CR70","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/00005053-199106000-00008","volume":"179","author":"LK Hsu","year":"1991","unstructured":"Hsu LK, et al. Treatment of bulimia nervosa with lithium carbonate. A controlled study. J Nerv Ment Dis. 1991;179(6):351\u20135.","journal-title":"J Nerv Ment Dis"},{"issue":"6","key":"713_CR71","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/00004714-199312000-00007","volume":"13","author":"SH Kennedy","year":"1993","unstructured":"Kennedy SH, et al. Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine. J Clin Psychopharmacol. 1993;13(6):415\u201322.","journal-title":"J Clin Psychopharmacol"},{"key":"713_CR72","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"J Higgins","year":"2011","unstructured":"Higgins J, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"3","key":"713_CR73","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1037\/0033-2909.86.3.638","volume":"86","author":"R Rosenthal","year":"1979","unstructured":"Rosenthal R. The file drawer problem and tolerance for null results. Psychol Bull. 1979;86(3):638\u201341.","journal-title":"Psychol Bull"},{"issue":"7414","key":"713_CR74","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"J Higgins","year":"2003","unstructured":"Higgins J, et al. Measuring inconsistency in meta-analyses. BMJ Brit Med J. 2003;327(7414):557.","journal-title":"BMJ Brit Med J"},{"issue":"9","key":"713_CR75","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1177\/070674379003500904","volume":"35","author":"DS Goldbloom","year":"1990","unstructured":"Goldbloom DS, Garfinkel PE. The serotonin hypothesis of bulimia nervosa: theory and evidence. Can J Psychiatry. 1990;35(9):741\u20134.","journal-title":"Can J Psychiatry"},{"issue":"3","key":"713_CR76","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/0022-3999(95)00640-0","volume":"40","author":"DS Goldbloom","year":"1996","unstructured":"Goldbloom DS, et al. The hormonal response to intravenous 5-hydroxytryptophan in bulimia nervosa. J Psychosom Res. 1996;40(3):289\u201397.","journal-title":"J Psychosom Res"},{"issue":"3","key":"713_CR77","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1037\/hea0000547","volume":"37","author":"CR Pacanowski","year":"2018","unstructured":"Pacanowski CR, et al. Psychological status and weight variability over eight years: results from Look AHEAD. Health Psychol. 2018;37(3):238\u201346.","journal-title":"Health Psychol"},{"issue":"2","key":"713_CR78","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.brainres.2003.08.032","volume":"992","author":"SR Hettes","year":"2003","unstructured":"Hettes SR, et al. Dual roles in feeding for AMPA\/kainate receptors: receptor activation or inactivation within distinct hypothalamic regions elicits feeding behavior. Brain Res. 2003;992(2):167\u201378.","journal-title":"Brain Res"},{"key":"713_CR79","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1192\/bjp.146.2.169","volume":"146","author":"PH Robinson","year":"1985","unstructured":"Robinson PH, Checkley SA, Russell GF. Suppression of eating by fenfluramine in patients with bulimia nervosa. Br J Psychiatry. 1985;146:169\u201376.","journal-title":"Br J Psychiatry"},{"key":"713_CR80","first-page":"Cd003391","volume":"4","author":"J Bacaltchuk","year":"2003","unstructured":"Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev. 2003;4:Cd003391.","journal-title":"Cochrane Database Syst Rev"},{"key":"713_CR81","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jad.2023.06.068","volume":"338","author":"M Fornaro","year":"2023","unstructured":"Fornaro M, et al. Psychopharmacology of eating disorders: systematic review and meta-analysis of randomized controlled trials. J Affect Disord. 2023;338:526\u201345.","journal-title":"J Affect Disord"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-023-00713-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-023-00713-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-023-00713-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T06:02:04Z","timestamp":1701583324000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-023-00713-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,2]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["713"],"URL":"https:\/\/doi.org\/10.1186\/s40360-023-00713-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3315948\/v1","asserted-by":"object"}]},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,2]]},"assertion":[{"value":"1 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"72"}}